Kynexis
Heramb Chadchankar, PhD is the Director & Head of Translational Science at Kynexis. Prior to this, Heramb worked as a Principal Scientist II at Novartis Institutes for BioMedical Research and as a Scientist at Alkermes. Heramb has a strong background in preclinical and clinical biomarker development, gene therapy, in vivo pharmacology, and neuroscience research. Heramb holds a Doctor of Philosophy (PhD) in Pharmacology/Neuroscience from the University of Eastern Finland.
This person is not in any offices
Kynexis
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.